Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Enfermedades Infecciosas Y Microbiologia Clinica
|
August 1, 1995
[2 cases of ocular infestation by Oestrus ovis]
E Boquet, S Escrivá, I Brun, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria
|
October 7, 2006
[Ocular toxicity by the use of ethambutol]
C Hernández Prats, S Escrivá Moscardó, F Martínez Pastor, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria
|
October 19, 2007
[Angioedema associated with enalapril]
F Llinares Tello, C Hernández Prats, A Sansano Clement, et al.
Reumatologia Clinica
|
July 29, 2011
[Not Available]
J Vicente, M T Gomis, S Escrivá, et al.
Revista De Medicina De La Universidad De Navarra
|
January 20, 2004
[Von Willebrand factor as an intermediate between hemostasis and angiogenesis of tumor origin]
I Gil-Bazo, V Catalán, J Páramo, et al.
ESMO Open
|
November 7, 2025
Comparing [<sup>18</sup>F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial
J J García-Mosquera, J M Pérez-García, M Ruiz-Borrego, et al.
ESMO Open
|
September 2, 2025
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
T Pascual, G Villacampa, M Oliveira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
N Harbeck, S Modi, L Pusztai, et al.
ESMO Open
|
May 11, 2026
Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project
R Sánchez-Bayona, J de Nicolás-Hernández, C Saura, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Enfermedades Infecciosas Y Microbiologia Clinica
|
August 1, 1995
[2 cases of ocular infestation by Oestrus ovis]
E Boquet, S Escrivá, I Brun, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria
|
October 7, 2006
[Ocular toxicity by the use of ethambutol]
C Hernández Prats, S Escrivá Moscardó, F Martínez Pastor, et al.
Farmacia Hospitalaria : Organo Oficial De Expresion Cientifica De La Sociedad Espanola De Farmacia Hospitalaria
|
October 19, 2007
[Angioedema associated with enalapril]
F Llinares Tello, C Hernández Prats, A Sansano Clement, et al.
Reumatologia Clinica
|
July 29, 2011
[Not Available]
J Vicente, M T Gomis, S Escrivá, et al.
Revista De Medicina De La Universidad De Navarra
|
January 20, 2004
[Von Willebrand factor as an intermediate between hemostasis and angiogenesis of tumor origin]
I Gil-Bazo, V Catalán, J Páramo, et al.
ESMO Open
|
November 7, 2025
Comparing [<sup>18</sup>F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial
J J García-Mosquera, J M Pérez-García, M Ruiz-Borrego, et al.
ESMO Open
|
September 2, 2025
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial
T Pascual, G Villacampa, M Oliveira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 23, 2025
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
N Harbeck, S Modi, L Pusztai, et al.
ESMO Open
|
May 11, 2026
Analysis of UGT1A1 germline variants in patients with advanced breast cancer treated with trastuzumab-deruxtecan: results from the PROCURE Project
R Sánchez-Bayona, J de Nicolás-Hernández, C Saura, et al.
Page
of 1